肿瘤伴同性诊断市场规模、份额及成长分析（按成分、适应症、技术、最终用户和地区）- 产业预测，2025-2032 年

肿瘤伴同性诊断市场规模预计在 2023 年达到 35 亿美元，2024 年达到 39.6 亿美元，2032 年达到 105.2 亿美元，预测期间（2025-2032 年）的复合年增长率为 13%。

随着个人化医疗（根据癌症患者的个人基因图谱制定治疗方案）的日益普及，伴同性诊断市场预计将显着增长。医学研究投入的增加和各种癌症发病率的上升将推动对这些诊断的需求，为肿瘤学领域的公司提供新的机会。此外，精准医疗技术的进步预计将进​​一步刺激需求。然而，复杂的法律规范、高昂的实施成本以及分子资料管理困难等挑战可能会阻碍市场的发展。总体而言，在技术创新和不断增长的治疗需求的推动下，肿瘤伴同性诊断领域有望扩大。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

肿瘤伴同性诊断市场规模（按成分和复合年增长率） (2025-2032)

• 市场概况
• 产品
• 服务

肿瘤伴同性诊断市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 病理学/诊断实验室
• 学术医疗中心

肿瘤伴同性诊断市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概况
• 乳癌
• 非小细胞肺癌
• 大肠直肠癌
• 白血病 黑色素瘤
• 摄护腺癌
• 其他的

肿瘤伴同性诊断市场规模（依技术及复合年增长率） (2025-2032)

• 市场概况
• 聚合酵素链锁反应（PCR）
• 次世代定序（NGS）
• 免疫组织化学 (IHC)
• 原位杂交（ISH）/萤光原位杂交（FISH）
• 其他技术

肿瘤伴同性诊断市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Roche Holding AG（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• Agilent Technologies, Inc.（USA）
• Abbott Laboratories（USA）
• BioMerieux SA（France）
• Siemens Healthineers AG（Germany）
• Danaher Corporation（USA）
• Foundation Medicine, Inc.（USA）
• Myriad Genetics, Inc.（USA）
• Guardant Health, Inc.（USA）
• Exact Sciences Corporation（USA）
• Illumina, Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• Bio-Rad Laboratories, Inc.（USA）
• Leica Biosystems（Germany）
• Sysmex Corporation（Japan）
• Horiba, Ltd.（Japan）
• Invitae Corporation（USA）
• NeoGenomics, Inc.（USA）

结论和建议

Companion Diagnostics for Oncology Market size was valued at USD 3.5 Billion in 2023 and is poised to grow from USD 3.96 Billion in 2024 to USD 10.52 Billion by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The companion diagnostics market is expected to see significant growth due to the increasing popularity of personalized medicine, which tailors treatment based on individual genetic profiles in cancer patients. Rising investments in medical research, coupled with the growing incidence of various cancers, will enhance demand for these diagnostics, presenting new opportunities for companies in the oncology sector. Additionally, advancements in precision medicine technology are likely to drive further demand. However, challenges such as complex regulatory frameworks, high implementation costs, and difficulties in managing molecular data may impede market development. Overall, the companion diagnostics for oncology sector is poised for expansion, driven by both technological innovations and increasing treatment needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Companion Diagnostics For Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Companion Diagnostics For Oncology Market Segmental Analysis

The global companion diagnostics for oncology market is segmented based on component, technology, end user, indication, and region. In terms of component, the market is segmented into products and services. In terms of end user, the market is segmented into hospitals, pathology/diagnostic laboratories, and academic medical centers. Based on indication, the market is bifurcated into breast cancer, non-small cell lung cancer, colorectal cancer, leukemia, melanoma, prostate cancer, and others. In terms of technology, the market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), in situ hybridization (ISH)/fluorescence in situ hybridization (FISH), and other technologies. Based on region, the market is segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa.

Driver of the Companion Diagnostics For Oncology Market

The Companion Diagnostics for Oncology market is significantly driven by the advancement of precision medicine. As technologies in this field evolve rapidly, they are accompanied by substantial investments in medical research and development. This surge in investment is largely fueled by the increasing demand for personalized cancer therapies, which aim to reduce side effects and enhance treatment effectiveness. Consequently, this growing emphasis on tailored treatment approaches is expected to contribute to a heightened demand for companion diagnostics, positioning them as essential tools in the management and treatment of oncology patients moving forward.

Restraints in the Companion Diagnostics For Oncology Market

One significant restraint impacting the Companion Diagnostics for Oncology market is the regulatory challenges posed by governmental bodies and authorities. The stringent guidelines and mandates governing the development of new companion diagnostics can complicate the approval process, resulting in delays. This rigorous compliance framework may hinder innovation and slow the progression of the market. As regulatory hurdles become more pronounced, they could impede the timely introduction of novel diagnostics, ultimately affecting the growth potential of the companion diagnostics sector in the oncology field. Therefore, navigating these regulatory landscapes is crucial for advancing market development.

Market Trends of the Companion Diagnostics For Oncology Market

The Companion Diagnostics for Oncology market is witnessing a notable trend toward biomarker discovery as companies aim to enhance their business scope and maximize revenue generation. By employing advanced genomic and proteomic technologies, organizations are not only identifying new biomarkers but also facilitating personalized treatment approaches that align with the evolving landscape of precision medicine. This strategic focus on biomarker innovation promises to drive market growth significantly, catering to the increasing demand for targeted therapies and improving patient outcomes. As the market continues to expand, investment in biomarker research will be crucial to staying competitive and capitalizing on emerging opportunities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Companion Diagnostics for Oncology Market Size by Component & CAGR (2025-2032)

• Market Overview
• Products
• Services

Global Companion Diagnostics for Oncology Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Pathology/Diagnostic Laboratories
• Academic Medical Centers

Global Companion Diagnostics for Oncology Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Leukemia, Melanoma
• Prostate Cancer
• Others

Global Companion Diagnostics for Oncology Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Immunohistochemistry (IHC)
• In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
• Other Technologies

Global Companion Diagnostics for Oncology Market Size & CAGR (2025-2032)

• North America (Component, End User, Indication, Technology)
  • US
  • Canada
• Europe (Component, End User, Indication, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Component, End User, Indication, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Component, End User, Indication, Technology)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Component, End User, Indication, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horiba, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations